Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a biopharmaceutical company focused on developing and commercializing therapies for unmet medical needs, has been navigating a complex landscape of ...

It’s critical to understand what a digitally savvy HCP is in 2025 and what’s impeding pharma's communications with this ...

U.K.-based ad agency DAIVID said Pfizer had a strong, positive message with its ad and scored high with intense positive emotions. The commercial was also a top performer with spikes in positive ...

Vanda Pharmaceuticals sees strong growth with Fanapt for bipolar I disorder, projects 2025 revenue up 6%-26%, and targets $1B by 2030.

In this process, royalty recipients often face the issue where multiple small future royalty streams cannot fulfill ongoing large lump-sum R&D funding needs. The mismatch is where Royalty Pharma ...

Shares of Vertex Pharmaceuticals, Inc. were in the spotlight in premarket trading Tuesday as the biotech company received ...

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

Pharmaceutical companies make drugs and vaccines ... Both licenses allow Knight to earn a portion of the drugs’ sales. The company has licenses for over 100 products and has strong positive ...

Founded in 1935 by Khwaja Abdul Ahmeid, Cipla operates through two segments: Pharmaceuticals and New Ventures. Cipla Limited specialises in developing medications, primarily treating respiratory ...

Swiss pharmaceutical giant Novartis on Friday reported better-than-expected sales in the fourth quarter. Fourth-quarter net sales rose 16% on a constant currency basis to $13.2 billion ...

Poxel eligible for royalties equaling 10% of all TWYMEEG ® net sales for 2024 and a one-time sales-based payment of JPY 500 million (EUR 3.1 million 3). Beyond 2024, Poxel expects to receive ...

Rua Dr. Diogo de Faria, 1087 – 9º andar – Vila Clementino 04037-003 São Paulo/SP - Brasil E-mail: scielo@scielo.org ...